로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > TLR3

TLR3

요약

Name:Toll like receptor 3
Target Synonym:CD283,TLR3,Toll Like Receptor 3,Toll-Like Receptor 3,CD283 Antigen,IIAE2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

TL3-R5253-MALS-HPLC
TLR3 MALS images

The purity of Rhesus macaque TLR3 Protein, Fc Tag (Cat. No. TL3-R5253) is more than 90% and the molecular weight of this protein is around 260-290 kDa verified by SEC-MALS.

TL3-M5255-MALS-HPLC
Human TLR3, Fc Tag (Cat. No. ) MALS images

The purity of Human TLR3, Fc Tag (Cat. No. TL3-M5255) is more than 90% and the molecular weight of this protein is around 235-287 kDa verified by SEC-MALS.

Synonym Name

TLR3,CD283,IIAE2

Background

Toll-like receptor 3 (TLR3) is also known as CD283, which belongs to the Toll-like receptor family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 / CD283 contains 22 LRR (leucine-rich) repeats, 1 LRRCT domain, 1 LRRNT domain and 1 TIR domain. TLR3 is expressed at high level in placenta and pancreas and also detected in CD11c+ immature dendritic cells. CD283 / TLR3 is only expressed in dendritic cells. TLR3 is the TLR that is expressed most strongly in the brain, especially in astrocytes, glia, and neurons. CD283 / TLR-3 is the key component of innate and adaptive immunity. TLR3 / CD283 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. TLR3 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Defects in TL-R3 are associated with herpes simplex encephalitis type 2 (HSE2).

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rintatolimod AMP-516; AMP-518 Approved Hemispherx Biopharma Inc Rintamod, Ampligen Argentina Fatigue Syndrome, Chronic Hemispherx Biopharma Inc 2017-01-01 HIV Infections; Ovarian Neoplasms; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Mesothelioma; Influenza, Human; Breast Neoplasms; Post-Acute COVID-19 Syndrome; Peritoneal Neoplasms; Colorectal Neoplasms; Fatigue Syndrome, Chronic; Fallopian Tube Neoplasms; HIV Seropositivity; Breast Neoplasms, Male Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
BO-112 BO-112 Phase 2 Clinical Highlight Therapeutics SL Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
CNTO-3157 PRV-300; CNTO-3157; JNJ-42915925 Phase 1 Clinical Centocor Ortho Biotech Inc, Morphosys Ag Colitis, Ulcerative; Asthma Details
Poly ICLC (Oncovir) Phase 2 Clinical National Institutes Of Health, Oncovir Inc Lymphoma, B-Cell; Carcinoma, Merkel Cell; Coronavirus Disease 2019 (COVID-19); Pancreatic Neoplasms; Glioblastoma; Mesothelioma; Osteosarcoma; Sarcoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Glioma; Lymphoma, T-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
PGV-001 PGV-001 Phase 1 Clinical Genentech Inc, Icahn School Of Medicine At Mount Sinai Neoplasms Details
CNTO-5 CNTO-5 Phase 1 Clinical Morphosys Ag Inflammation Details
TR-987 Z-101; GLYC-101; MG-3601 Phase 2 Clinical Kazia Therapeutics Wounds and Injuries; Varicose Ulcer Details
Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS VXA-NVV-201 Phase 2 Clinical Vaxart Inc Norovirus Infections Details
Monovalent norovirus Vaccine (Vaxart) VXA-G1-1-NN; VXA-G1.1-NN Phase 2 Clinical Vaxart Inc Norovirus Infections Details

This web search service is supported by Google Inc.

totop